5 results about "Respiratory epithelium" patented technology

The present invention relates to a method for producing respiratory organoids by proliferating and differentiating respiratory epithelial cells. [Solution] Unlike conventional respiratory organoids in which epithelial cells present at the apical end of the respiratory tract develop inside the organoid, the respiratory organoid of the present invention has a morphology in which the ciliated structure, which is made up of epithelial cells, is located in the outer layer of the organoid, secretory cells are located inside, and stem cell-like basal cells present at the base of the respiratory tissue are also located inside the organoid. This morphology is similar to that of actual respiratory tissue and has been observed to exhibit normal functions of epithelial cells, such as the motility of ciliated cells. Therefore, by manufacturing organoids using the manufacturing method of the present invention, it is possible to manufacture respiratory organoids that can accurately mimic actual tissue.

The invention belongs to the technical field of biological medicines, and discloses a probiotic composition for preventing and treating respiratory tract infection as well as application and a product thereof. The probiotic composition provided by the invention contains the bifidobacterium longum subsp. Infantis i18 and the casei paracasei N1115. Compared with other combinations of bifidobacterium and casei paracasei, the specific combination of the bifidobacterium longum subsp. Infantis i18 and the casei paracasei N1115 not only has better adhesion to respiratory tract epithelial cells, but also can more remarkably reduce inflammatory response of inflammatory cells, effectively repair damaged respiratory tract epithelial cells and improve the respiratory tract epithelial cell repair effect. And the two compounds also show a more excellent synergistic effect in the aspect of inhibiting the growth of staphylococcus aureus. After breast milk oligosaccharide is added on the basis, the adhesive capacity to epithelial cells of the respiratory tract and the bacteriostatic activity to target pathogenic bacteria can be further enhanced. The invention can be applied to the fields of preparation of related food or medicines for prevention, treatment or adjuvant treatment of respiratory tract infection and the like.

The present disclosure provides a use of a bacterial cellulose in treating and preventing airway diseases, especially the use in the treatment and prevention of inflammatory airway diseases associated with an impairment in airway epithelial cells such as asthma.

The application belongs to the technical field of biological medicine, and discloses application of xanthine in repairing respiratory epithelial injury drugs and a chronic obstructive pulmonary disease (COPD) organoid model construction and evaluation method. In view of the defects that existing treatment focuses on inflammation control, relies on multi-drug combination, lacks epithelial repair targeting and has low pathological similarity in vitro model, an airway-alveolus organoid model is innovatively constructed, the pathological chain of COPD airway injury-alveolus destruction can be completely reproduced, and a multi-dimensional evaluation system is established. Based on the model, it is first proved that xanthine single drug can significantly promote proliferation of damaged airway organoid cells, inhibit abnormal apoptosis, selectively down-regulate release of inflammatory factors such as TNF-alpha and CXCL1, promote alveolus organoid AT2 cell proliferation and regeneration, and repair alveolus homeostasis at a concentration of 20-100 muM without combination with other drugs. Xanthine is an endogenous purine metabolite, is safe and low-toxic, solves the pain points of existing drug combination dependence and side effects, and realizes upgrading from inflammation control to structure repair. Xanthine can be made into oral or respiratory tract local preparations, is suitable for repairing epithelial injury of respiratory diseases such as COPD and asthma, is suitable for a wide range of people, has significant clinical and industrialization values, and the innovative model also provides a reliable tool for related drug research and development.

The invention provides a metabolism reprogramming culture medium, a metabolism reprogramming mesenchymal stem cell and a preparation method and application thereof, and relates to the technical field of stem cell culture, the metabolism reprogramming culture medium contains glucose and cell factors released by injured respiratory tract epithelial cells; the cell factors comprise at least one of IL-6 (interleukin-6), IL-8 (interleukin-8), IL-1beta (interleukin-1beta), TNF (tumor necrosis factor)-alpha, IFN (interferon)-gamma, MCP-1 (microcytidylcholine)-1, TGF (transforming growth factor)-beta, FGF2 ( And the content of glucose is 4000 to 5000 mg / L. In a high-glucose environment, damaged respiratory tract epithelial cells release cytokines to form a multi-factor regulation network, metabolism reprogramming of MSCs can be specifically induced, an efficient MSCs treatment product with definite functions is obtained, the problem that in the prior art, a culture medium is difficult to accurately simulate the influence of a disease complex microenvironment on the performance of MSCs is solved, and the MSCs treatment effect is improved. Therefore, the function enhancement effect of the preprocessed MSCs is limited and unstable.